Key facts
- This page summarizes Elizabeth Crowley's Form 4 filing for Celldex Therapeutics, Inc. (CLDX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Jun 2024, 16:04.
Elizabeth Crowley - 14 Jun 2024 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)
- Reporting relationship
- SR. VP & CPDO
- Issuer ticker
- CLDX
- Reported as of
- 14 Jun 2024
- Net transaction value
- -$734,562
- SEC form
- 4
- Accepted by SEC
- 18 Jun 2024, 16:04:13 UTC
- Prior SEC filing
- 17 Jun 2024
- Next SEC filing
- 09 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sam Martin, attorney-in-fact for Elizabeth Crowley
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Elizabeth Crowley filed Form 4 for Celldex Therapeutics, Inc. (CLDX) on 18 Jun 2024.
Change
- Previous filing in this sequence was filed on 17 Jun 2024.
- Current net transaction value: -$734,562.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLDX
transaction
Common Stock
Options Exercise
- Transaction value
- $311,400
- Shares
- +30,000
- Change %
- +331%
- Price
- $10.38
- Shares after
- 39,074
- Date
- 14 Jun 2024
- Ownership
- Direct
CLDX
transaction
Common Stock
Sale
- Transaction value
- $1,045,962
- Shares
- -30,000
- Change %
- -77%
- Price
- $34.87
- Shares after
- 9,074
- Date
- 14 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLDX
transaction
Derivative
Incentive Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -30,000
- Change %
- -39%
- Price
- $0.000000
- Shares after
- 46,500
- Date
- 14 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $10.38
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.51 to $35.39 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
Footnote F2
As of June 18, 2024, the option is fully vested.